Researchers developed a deep learning-driven MASLD classification system for precision risk management.
Key Details
- 1Study analyzed 1,111 liver biopsies to train a deep LASSO model using six clinical indicators.
- 2Algorithm defined four MASLD subtypes with distinct risk profiles for hepatic and extrahepatic complications.
- 3External validation performed in cohorts of 6,172 and 7,406 adults; clustering was consistent.
- 4Cluster 4 displayed highest risk for combined cardiovascular, liver, and kidney complications, and high frequency of PNPLA3 risk alleles.
- 5The classification intends to tailor interventions, such as prioritizing fibrosis screening or cardiorenal protection, by subtype.
Why It Matters
The use of advanced AI/machine learning in clinical stratification sets a precedent for data-driven, precision approaches in metabolic and cardiometabolic disease management. Implications exist for integration with imaging biomarkers and improving targeted clinical decision-making in radiology and hepatology.
Source
EurekAlert
Related News
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.
•EurekAlert
AI Unlocks Hidden Brain Lesions in Multiple Sclerosis via MRI
AI-enabled image processing reveals invisible cortical lesions in MRI scans of MS patients, advancing diagnosis and research.
•EurekAlert
AI-Driven Molecular Profiling Enhances Thrombosis Risk Prediction
Researchers create an AI model integrating genetic, clinical, and transcriptomic data to identify individuals at risk for thrombosis.